SOCS1 and neoplasm: Interestingly, SOCS1 could reduce PD-L1 expression and restore the activation of tumor-infiltrating CD8+ T cells, which highlighted its potential as an immune checkpoint inhibitor in OV (Nakagawa et al., 2018).